SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study

Aug. 09, 2022 9:33 AM ETSELLAS Life Sciences Group, Inc. (SLS)By: Dania Nadeem, SA News Editor2 Comments

Cancer cells

Mohammed Haneefa Nizamudeen/iStock via Getty Images

  • SELLAS Life Sciences (NASDAQ:SLS) is trading 9.2% higher on Tuesday after the company announced results from preclinical studies for its CDK9 inhibitor, GFH009, to treat solid cancer and acute myeloid leukemia (AML) cell lines.
  • The drug showed significant anti-tumor effects in all four selected cell lines, and in three out of the four cell lines, GFH009 inhibited cancer cell growth by 90% to 100%.
  • The following cell lines were selected for the studies:
  • RH30: a pediatric soft tissue sarcoma cell line.
  • NCI-H209: a small cell lung cancer cell line.
  • SKOV-3: an ovarian cancer cell line.
  • OCI-AML-2: an AML cell line.
  • "The data from preclinical studies that we are reporting today demonstrates that certain cancer cell lines, whose survival depends on specific changes in the cell, can be identified and treated with GFH009," said Dragan Cicic, Senior Vice President, Clinical Development, of SELLAS.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.